We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.58 | 0.55% | 106.60 | 8,357 | 14:17:28 |
From Jun 2023 to Jun 2024
By Mauro Orru
Novartis's generics-and-biosimilars division Sandoz was granted marketing authorization from the European Commission to commercialize and distribute Tyruko to treat relapsing forms of multiple sclerosis in the bloc.
The company said Tuesday that Sandoz has the right to commercialize and distribute Tyruko in markets where it is approved through an exclusive agreement with Polpharma Biologics, which makes the treatment. Polpharma Biologics will maintain responsibilities for development of the medicine.
"Today's approval brings us one step closer to reducing the burden of this disease for those living with multiple sclerosis in Europe by making the life-enhancing treatments they need more accessible," said Rebecca Guntern, President for Europe at Sandoz.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
(END) Dow Jones Newswires
September 26, 2023 01:48 ET (05:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
